141 related articles for article (PubMed ID: 19022670)
1. Potent inhibitors of HCV-NS3 protease derived from boronic acids.
Venkatraman S; Wu W; Prongay A; Girijavallabhan V; George Njoroge F
Bioorg Med Chem Lett; 2009 Jan; 19(1):180-3. PubMed ID: 19022670
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.
Chen KX; Njoroge FG; Prongay A; Pichardo J; Madison V; Girijavallabhan V
Bioorg Med Chem Lett; 2005 Oct; 15(20):4475-8. PubMed ID: 16112859
[TBL] [Abstract][Full Text] [Related]
3. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
4. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
6. Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.
Han W; Jiang X; Hu Z; Wasserman ZR; Decicco CP
Bioorg Med Chem Lett; 2005 Aug; 15(15):3487-90. PubMed ID: 15982872
[TBL] [Abstract][Full Text] [Related]
7. P4 cap modified tetrapeptidyl alpha-ketoamides as potent HCV NS3 protease inhibitors.
Sun DX; Liu L; Heinz B; Kolykhalov A; Lamar J; Johnson RB; Wang QM; Yip Y; Chen SH
Bioorg Med Chem Lett; 2004 Aug; 14(16):4333-8. PubMed ID: 15261297
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
[TBL] [Abstract][Full Text] [Related]
10. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
Slater MJ; Amphlett EM; Andrews DM; Bamborough P; Carey SJ; Johnson MR; Jones PS; Mills G; Parry NR; Somers DO; Stewart AJ; Skarzynski T
Org Lett; 2003 Nov; 5(24):4627-30. PubMed ID: 14627400
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2005 Oct; 48(20):6229-35. PubMed ID: 16190750
[TBL] [Abstract][Full Text] [Related]
12. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
Wei HY; Lu CS; Lin TH
J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics.
Goudreau N; Brochu C; Cameron DR; Duceppe JS; Faucher AM; Ferland JM; Grand-Maître C; Poirier M; Simoneau B; Tsantrizos YS
J Org Chem; 2004 Sep; 69(19):6185-201. PubMed ID: 15357576
[TBL] [Abstract][Full Text] [Related]
14. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Dahl G; Sandström A; Akerblom E; Danielson UH
Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
[TBL] [Abstract][Full Text] [Related]
15. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
[TBL] [Abstract][Full Text] [Related]
16. Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease.
Duan D; Li Z; Luo H; Zhang W; Chen L; Xu X
Bioorg Med Chem Lett; 2004 Dec; 14(24):6041-4. PubMed ID: 15546725
[TBL] [Abstract][Full Text] [Related]
17. P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease.
Priestley ES; De Lucca I; Ghavimi B; Erickson-Viitanen S; Decicco CP
Bioorg Med Chem Lett; 2002 Nov; 12(21):3199-202. PubMed ID: 12372533
[TBL] [Abstract][Full Text] [Related]
18. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
Llinàs-Brunet M; Bailey MD; Ghiro E; Gorys V; Halmos T; Poirier M; Rancourt J; Goudreau N
J Med Chem; 2004 Dec; 47(26):6584-94. PubMed ID: 15588093
[TBL] [Abstract][Full Text] [Related]
19. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.
Venkatraman S; Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu YT; Lovey R; Hendrata S; Huang Y; Pan W; Parekh T; Pinto P; Popov V; Pike R; Ruan S; Santhanam B; Vibulbhan B; Wu W; Yang W; Kong J; Liang X; Wong J; Liu R; Butkiewicz N; Chase R; Hart A; Agrawal S; Ingravallo P; Pichardo J; Kong R; Baroudy B; Malcolm B; Guo Z; Prongay A; Madison V; Broske L; Cui X; Cheng KC; Hsieh Y; Brisson JM; Prelusky D; Korfmacher W; White R; Bogdanowich-Knipp S; Pavlovsky A; Bradley P; Saksena AK; Ganguly A; Piwinski J; Girijavallabhan V; Njoroge FG
J Med Chem; 2006 Oct; 49(20):6074-86. PubMed ID: 17004721
[TBL] [Abstract][Full Text] [Related]
20. Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease.
Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2006 Jan; 49(2):567-74. PubMed ID: 16420042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
